Combination may offer a substitute to basal-bolus insulin in people with type 2 diabetes inadequately controlled with daily basal insulin.

called Insulin Icodec, which is an advancement in diabetes treatment. Although the drug has been approved by the European ...

Today, patients on insulin receive injections daily, or even more often, but both companies are working to change that.

From a baseline HbA1 of 8.9%, the once-weekly insulin icodec achieved a superior reduction in estimated HbA1 of -1.68%-points compared with -1.31%-points for once-daily basal insulins.

Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for ...

For people with type 1 diabetes, management burden including suboptimal insulin preparations remains a major barrier to ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Novo Nordisk already has regulatory approvals for its once-weekly insulin, icodec. In Europe, Canada, Australia, Japan, and Switzerland, this product is marketed as Awiqli for the treatment of ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

Insulin efsitora was able to lower A1C in patients with type 1 diabetes but more patients experienced severe hypoglycemic ...